Coherus Oncology (CHRS) Cost of Revenue (2019 - 2026)

Coherus Oncology has reported Cost of Revenue for 8 years, with the latest figure at $3.8 million in Q1 2026.

• Quarterly Cost of Revenue rose 43.76% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 million (up 50.64% YoY) and the FY2025 annual result came in at $13.8 million, up 58.29% from the prior year.
• Cost of Revenue declined to $3.8 million in Q1 2026 per CHRS's latest filing, from $4.0 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $84.6 million in Q4 2023 and troughed at $1.4 million in Q1 2024.
• A 5-year average of $15.0 million and a median of $4.0 million in 2025 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue jumped 495.46% in 2023, then sank 96.75% in 2024.
• Over 5 years, Cost of Revenue stood at $14.2 million in 2022, then surged by 495.46% to $84.6 million in 2023, then tumbled by 96.75% to $2.8 million in 2024, then soared by 47.09% to $4.0 million in 2025, then retreated by 5.71% to $3.8 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.8 million, $4.0 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.